A Phase 1 interventional study of BG-T0050 in Diffuse Large B-Cell Lymphoma and B-Cell Malignancies, sponsored by BeOne Medicines. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by BeOne Medicines · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines — 3 open to participants now, 3 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · BeOne Medicines.
Among the 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 4 in phase 1, and was the 9th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →3 of the 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines are open now, in 12 countries. Recruiting first, the newest first:
BeOne Medicines · Sites in United States, Australia, Brazil and 13 more countries
Ages 18+
BeOne Medicines
Ages 18+
By country, each count listing its studies:
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6
First in 2017; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 66 across the 10 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the safety and tolerability of BG-T0050 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in adults with DLBCL and other aggressive B-cell malignancies
Diffuse large B-cell lymphoma (DLBCL) is a fast-growing blood cancer that affects a type of white blood cell called B-cell lymphocytes. The cancer cells most commonly develop in the lymph nodes but may also spread to tissues and organs outside the lymph nodes.
BG-T0050 is an antibody-based immunotherapy drug that is designed to attach to both cancer cells and healthy immune cells (called T-cells). This brings the T-cells into close contact with the cancer cells, helping the T-cells find and destroy the cancer cells.
The purpose of this study is to test whether BG-T0050 is safe and if it can help treat adults with diffuse large B-cell lymphoma or other aggressive B-cell malignancies. The main goal of the study is to test the safety and tolerability of BG-T0050 and to identify the recommended dose and dosing schedule in participants with DLBCL and other aggressive B-cell malignancies.
This study consists of 2 parts, one called dose escalation and one called dose expansion. During the dose escalation part, the study doctors will test different doses of the study drug to find the recommended dose that people can take without having serious side effects. During the dose expansion part, the study doctors will test the study drug in a larger number of people using the dose[s] identified from dose escalation.
The study will enroll approximately 70 adult participants at multiple centers worldwide with DLBCL and other aggressive B-cell malignancies.
The overall time to participate in this study is 24 months. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of any of the below according to World Health Organization (WHO) classification
Exclusion Criteria:
Recent prior therapies, prior to the first dose of study drug:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequential cohorts of increasing dose levels of BG-T0050 will be evaluated as monotherapy.
Drug: BG-T0050
The recommended dose(s) for expansion (RDFE) for BG-T0050 from Part 1a will be evaluated.
Drug: BG-T0050
Administered subcutaneously
Part 1a Dose Escalation: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
Time frame: Approximately 1 Month
Part 1a and Part 1b: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)
Time frame: From first dose until 30 days after the last dose; approximately 13 months
Overall Response Rate (ORR) Assessed by the Investigator
ORR is defined as the percentage of participants with a best overall response of partial response or better per the Lugano Classification for non-Hodgkin lymphoma
Time frame: Approximately 24 months
Complete Response Rate (CRR)
CRR is defined as the percentage of patients with best overall response of complete response per the Lugano Classification
Time frame: Approximately 24 months
Duration of Response (DOR)
DOR is defined as the time from the first response to documented disease progression or death due to any cause, whichever occurs first
Time frame: Approximately 24 months
Time to Response (TTR)
TRR is defined as the time from first dose to the first response
Time frame: Approximately 24 months
Maximum Observed Plasma Concentration (Cmax) of BG-T0050
Time frame: Up to 1 month
Trough Concentration (Ctrough) of BG-T0050
Time frame: Up to 13 months
Area Under the Plasma Concentration-time Curve (AUC) of BG-T0050
Time frame: Up to 13 months
Serum Concentration of BG-T0050
Time frame: Up to 13 months
Percentage of Patients Developing Antidrug Antibodies Against BG-T0050
Time frame: Up to 13 months
No study locations are listed for this record.
Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beonemedicines.com
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Oct 2029, 35 months later.
Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's planned 35 months is below that.
Counting every sponsor, half of 195 studies reached it within 53 months; a quarter within 35 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large B-Cell, Diffuse →